TAS-CP383-01 A MULTI-CENTER, OPEN LABEL, PHASE 1/2 STUDY OF CP-383, AN ORAL DUAL DHODH AND TEAD4 INHIBITOR, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
- Phase I
- Trial Category: Other Solid Tumor
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha, NE location
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields